LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PrEP IN A SHIV RHESUS MACAQUE MODEL
The ability of daily oral preexposure prophylaxis (PrEP) to effectively reduce the risk of contracting HIV is strongly dependent on high medication adherence, which is not uniformly achieved among people at risk for HIV. Long-acting agents can circumvent the need for daily dosing while providing long-term protection. Lenacapavir (LEN), an investigational small molecule inhibitor of…